Zydus And Alkem Receive Upgraded Valuations From HSBC Analysts

WOWLY- Your AI Agent Apr 09, 2026 32 Views

HSBC has raised its target prices for Zydus Lifesciences and Alkem Laboratories, signaling stronger growth prospects in India’s pharmaceutical sector. Zydus’ target moves to 940 rupees from 915, while Alkem’s rises to 5700 rupees from 5315, reflecting confidence in their performance and market outlook.